Live attenuated Shigella dysenteriae type 1 vaccine strains overexpressing shiga toxin B subunit

Infection and Immunity

Volumn 79, Issue 12, 2011, Pages 4912-4922

  Wu, Tao ^a   Grassel, Christen ^a   Levine, Myron M ^a   Barry, Eileen M ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL TOXIN; INTERLEUKIN 8; LIVE VACCINE; NEUTRALIZING ANTIBODY; SHIGA TOXIN; SHIGA TOXIN B; UNCLASSIFIED DRUG; BACTERIAL VACCINE; BACTERIUM ANTIBODY; STXB TOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; CELL INVASION; CHROMOSOME; COLONY FORMING UNIT; DRUG ACTIVITY; DRUG SCREENING; ENZYME ACTIVITY; FEMALE; GENE DELETION; HUMAN; IMMUNOGENICITY; NONHUMAN; PLASMID; PRIORITY JOURNAL; SEROTYPE; SHIGELLA DYSENTERIAE; ANIMAL; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; GUINEA PIG; HELA CELL; IMMUNOLOGY; METABOLISM; PATHOGENICITY; SHIGELLOSIS; VIRULENCE;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; DYSENTERY, BACILLARY; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, BACTERIAL; GUINEA PIGS; HELA CELLS; HUMANS; SHIGA TOXINS; SHIGELLA DYSENTERIAE; VACCINES, ATTENUATED; VIRULENCE;

EID: 84855733490     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.05814-11     Document Type: Article

References (54)

1. Acheson, D. W., M. M. Levine, J. B. Kaper, and G. T. Keusch. 1996. Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR. Infect. Immun. 64:355-357.
2. Altboum, Z., M. M. Levine, J. E. Galen, and E. M. Barry. 2003. Genetic characterization and immunogenicity of coli surface antigen 4 from enterotoxigenic Escherichia coli when it is expressed in a Shigella live-vector strain. Infect. Immun. 71:1352-1360.
3. Barry, E. M., J. Wang, T. Wu, T. Davis, and M. M. Levine. 2006. Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model. Vaccine 24:3727-3734.
4. Bloom, P. D., et al. 1994. Haemolytic-uraemic syndrome in adults with resistant Shigella dysenteriae type I. Lancet 344:206.
5. Bogaerts, J., et al. 1985. Shigella and Salmonella species from Kigali (Rwanda) (1976-1982). Ann. Soc. Belg. Med. Trop. 65:281-292.
6. Boyd, B., S. Richardson, and J. Gariepy. 1991. Serological responses to the B subunit of Shiga-like toxin 1 and its peptide fragments indicate that the B subunit is a vaccine candidate to counter action of the toxin. Infect. Immun. 59:750-757.
7. Brosius, J., M. Erfle, and J. Storella. 1985. Spacing of the -10 and -35 regions in the tac promoter. Effect on its in vivo activity. J. Biol. Chem. 260:3539-3541.
8. Butterton, J. R., E. T. Ryan, D. W. Acheson, and S. B. Calderwood. 1997. Coexpression of the B subunit of Shiga toxin 1 and EaeA from enterohemorrhagic Escherichia coli in Vibrio cholerae vaccine strains. Infect. Immun. 65:2127-2135.
9. Cohen, D., et al. 1996. Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers. Infect. Immun. 64:4074-4077.
10. Datsenko, K. A., and B. L. Wanner. 2000. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc. Natl. Acad. Sci. U. S. A. 97:6640-6645.
11. Donnenberg, M. S., and J. B. Kaper. 1991. Construction of an eae deletion mutant of enteropathogenic Escherichia coli by using a positive-selection suicide vector. Infect. Immun. 59:4310-4317.
12. DuPont, H. L., et al. 1972. Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection. J. Infect. Dis. 125:12-16.
13. DuPont, H. L., M. M. Levine, R. B. Hornick, and S. B. Formal. 1989. Inoculum size in shigellosis and implications for expected mode of transmission. J. Infect. Dis. 159:1126-1128.
14. Farfan, M. J., C. S. Toro, E. M. Barry, and J. P. Nataro. 2011. Shigella enterotoxin-2 is a type III effector that participates in Shigella-induced interleukin 8 secretion by epithelial cells. FEMS Immunol. Med. Microbiol. 61:332-339.
15. Fasano, A., et al. 1995. Shigella enterotoxin 1: an enterotoxin of Shigella flexneri 2a active in rabbit small intestine in vivo and in vitro. J. Clin. Invest. 95:2853-2861.
16. Ferreccio, C., et al. 1991. Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile. Am. J. Epidemiol. 134:614-627.
17. Gangarosa, E. J., et al. 1970. Epidemic Shiga bacillus dysentery in Central America. II. Epidemiologic studies in 1969. J. Infect. Dis. 122:181-190.
18. Gemski, P., Jr., A. Takeuchi, O. Washington, and S. B. Formal. 1972. Shigellosis due to Shigella dysenteriae. 1. Relative importance of mucosal invasion versus toxin production in pathogenesis. J. Infect. Dis. 126:523-530.
19. Houdouin, V., et al. 2004. A pediatric cluster of Shigella dysenteriae serotype 1 diarrhea with hemolytic uremic syndrome in 2 families from France. Clin. Infect. Dis. 38:e96-e99.
20. Inouye, S., and M. Inouye. 1985. Up-promoter mutations in the lpp gene of Escherichia coli. Nucleic Acids Res. 13:3101-3110.
21. Koprowski, H., et al. 2000. Attenuated Shigella flexneri 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic Escherichia coli. Infect. Immun. 68:4884-4892.
22. Kotloff, K. L., et al. 2004. Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208. J. Infect. Dis. 190:1745-1754.
23. Kotloff, K. L., et al. 2007. Safety and immunogenicity of CVD 1208S, a live, oral ΔguaBA Δsen Δset Shigella flexneri 2a vaccine grown on animal-free media. Hum. Vaccin. 3:268-275.
24. Kotloff, K. L., et al. 1999. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull. World Health Organ. 77:651-666.
25. Levine, M. M., et al. 1973. Pathogenesis of Shigella dysenteriae 1 (Shiga) dysentery. J. Infect. Dis. 127:261-270.
26. Levine, M. M., K. L. Kotloff, E. M. Barry, M. F. Pasetti, and M. B. Sztein. 2007. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat. Rev. Microbiol. 5:540-553.
27. Marcato, P., T. P. Griener, G. L. Mulvey, and G. D. Armstrong. 2005. Recombinant Shiga toxin B-subunit-keyhole limpet hemocyanin conjugate vaccine protects mice from shigatoxemia. Infect. Immun. 73:6523-6529.
28. Marques, L. R., M. A. Moore, J. G. Wells, I. K. Wachsmuth, and A. D. O'Brien. 1986. Production of Shiga-like toxin by Escherichia coli. J. Infect. Dis. 154:338-341.
29. Mata, L. J., E. J. Gangarosa, A. Caceres, D. R. Perera, and M. L. Mejicanos. 1970. Epidemic Shiga bacillus dysentery in Central America. I. Etiologic investigations in Guatemala, 1969. J. Infect. Dis. 122:170-180.
30. McCormick, B. A., S. P. Colgan, C. Delp-Archer, S. I. Miller, and J. L. Madara. 1993. Salmonella typhimurium attachment to human intestinal epithelial monolayers: transcellular signalling to subepithelial neutrophils. J. Cell Biol. 123:895-907.
31. McCormick, B. A., M. I. Fernandez, A. M. Siber, and A. T. Maurelli. 1999. Inhibition of Shigella flexneri-induced transepithelial migration of polymorphonuclear leucocytes by cadaverine. Cell. Microbiol. 1:143-155.
32. McKenzie, R., et al. 2008. Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate. Vaccine 26:3291-3296.
33. Mel, D., E. J. Gangarosa, M. L. Radovanovic, B. L. Arsic, and S. Litvinjenko. 1971. Studies on vaccination against bacillary dysentery. 6. Protection of children by oral immunization with streptomycin-dependent Shigella strains. Bull. World Health Organ. 45:457-464.
34. Mel, D. M., A. L. Terzin, and L. Vuksic. 1965. Studies on vaccination against bacillary dysentery. 3. Effective oral immunization against Shigella flexneri 2a in a field trial. Bull. World Health Organ. 32:647-655.
35. Mhalu, F. S., W. K. Moshi, and I. Mbaga. 1984. A bacillary dysentery epidemic in Dar es Salaam, Tanzania. J. Diarrhoeal Dis. Res. 2:217-222.
36. Nakamura, K., and M. Inouye. 1979. DNA sequence of the gene for the outer membrane lipoprotein of E. coli: an extremely AT-rich promoter. Cell 18:1109-1117.
37. Nataro, J. P., et al. 1995. Identification and cloning of a novel plasmidencoded enterotoxin of enteroinvasive Escherichia coli and Shigella strains. Infect. Immun. 63:4721-4728.
38. National Institute of Allergy and Infectious Diseases. 2003. NIAID biodefense research agenda for category B and C priority pathogens. NIH publication no. 03-5315. National Institute of Allergy and Infectious Diseases, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD.
39. Neill, R. J., P. Gemski, S. B. Formal, and J. W. Newland. 1988. Deletion of the Shiga toxin gene in a chlorate-resistant derivative of Shigella dysenteriae type 1 that retains virulence. J. Infect. Dis. 158:737-741.
40. Noriega, F. R., F. M. Liao, S. B. Formal, A. Fasano, and M. M. Levine. 1995. Prevalence of Shigella enterotoxin 1 among Shigella clinical isolates of diverse serotypes. J. Infect. Dis. 172:1408-1410.
41. Noriega, F. R., et al. 1996. Engineered ΔguaB-A ΔvirG Shigella flexneri 2a strain CVD 1205: construction, safety, immunogenicity, and potential efficacy as a mucosal vaccine. Infect. Immun. 64:3055-3061.
42. Noriega, F. R., G. Losonsky, J. Y. Wang, S. B. Formal, and M. M. Levine. 1996. Further characterization of ΔaroA ΔvirG Shigella flexneri 2a strain CVD 1203 as a mucosal Shigella vaccine and as a live-vector vaccine for delivering antigens of enterotoxigenic Escherichia coli. Infect. Immun. 64: 23-27.
43. Oaks, E. V., M. E. Wingfield, and S. B. Formal. 1985. Plaque formation by virulent Shigella flexneri. Infect. Immun. 48:124-129.
44. Parsot, C. 2009. Shigella type III secretion effectors: how, where, when, for what purposes? Curr. Opin. Microbiol. 12:110-116.
45. Phalipon, A., and P. J. Sansonetti. 2007. Shigella's ways of manipulating the host intestinal innate and adaptive immune system: a tool box for survival? Immunol. Cell Biol. 85:119-129.
46. Pozsgay, V., et al. 1999. Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1. Proc. Natl. Acad. Sci. U. S. A. 96:5194-5197.
47. Rahaman, M. M., M. M. Khan, K. M. Aziz, M. S. Islam, and A. K. Kibriya. 1975. An outbreak of dysentery caused by Shigella dysenteriae type 1 on a coral island in the Bay of Bengal. J. Infect. Dis. 132:15-19.
48. Sadorge, C., et al. 2008. Phase 1 clinical trial of live attenuated Shigella dysenteriae type-1 ΔicsA Δent Δfep ΔstxA:HgR oral vaccine SC599 in healthy human adult volunteers. Vaccine 26:978-987.
49. Sereny, B. 1955. Experimental shigella keratoconjunctivitis: a preliminary report. Acta Microbiol. Acad. Sci. Hung. 2:293-296.
50. Shiga, K. 1898. On the cause of dysentery in Japan. Zentralbl. Bakteriol. Parasitenkd. Abt. 1 23:599.
51. Taylor, D. N., et al. 1993. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids. Infect. Immun. 61:3678-3687.
52. Vargas, M., J. Gascon, M. T. Jimenez De Anta, and J. Vila. 1999. Prevalence of Shigella enterotoxins 1 and 2 among Shigella strains isolated from patients with traveler's diarrhea. J. Clin. Microbiol. 37:3608-3611.
53. Venkatesan, M. M., et al. 2002. Construction, characterization, and animal testing of WRSd1, a Shigella dysenteriae 1 vaccine. Infect. Immun. 70:2950-2958.
54. Venkatesan, M. M., and R. T. Ranallo. 2006. Live-attenuated Shigella vaccines. Expert Rev. Vaccines 5:669-686.